High Content Imaging can be applied to many steps in the drug discovery process. It can be used as a primary high-throughput screening tool to analyze potential leads, optimizing your hit identification strategies. As your drug targets or lead compounds progress into lead optimization, we can help you visualize and quantify phenotypic changes in more complex cellular systems to predict success in vivo.

Hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease of the cardiac sarcomere. In this case study, we created an HCM disease model from iPSC-derived cardiomyocytes. We measured BNP expression through overnight ET-1 exposure by immunofluorescence microscopy (see visual below).

After successful assay validation, we screened ~5000 data points including >1800 approved drugs, and a thousand further compounds with known mechanism of action. Hits were confirmed via three distinct assays; NT-proBNP AlphaLISA assay, AlphaLISATruHits assay (deselect false positives), and intracellular expression assessed by a HCI secondary assay.

Click here to read the full case study: Hypertrophic cardiomyopathy

Would you like to know more about our High Content Imaging assay service?

We're here to listen to your project plans, questions and challenges, and to co-develop a solution that fits your specifications. Please leave your details and message in the form below and we will get back to you as soon as possible.